Roivant Sciences (NASDAQ:ROIV) Issues Quarterly Earnings Results

Roivant Sciences (NASDAQ:ROIV) released its quarterly earnings data on Wednesday. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.57, FiscalAI reports. The company had revenue of $2.52 million for the quarter, compared to the consensus estimate of $3.41 million. Roivant Sciences had a negative return on equity of 19.04% and a negative net margin of 6,079.94%.During the same period last year, the business posted ($0.29) EPS.

Here are the key takeaways from Roivant Sciences’ conference call:

• Roivant reported encouraging preliminary open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, with about 73% ACR20, over 50% ACR50, and more than one-third ACR70 responses in a heavily refractory population.
• The company said the RA data looked especially strong in the JAK- and TNF-refractory subgroup, and management emphasized that the treatment was safe and well-tolerated with no new drug-related safety signals identified.
• Roivant expects to use the RA results, along with additional patient-level analysis, to engage FDA on the future development path for IMVT-1402 later this year, including how many registrational studies may ultimately be needed.
• For mosliciguat in PH-ILD, management highlighted strong Phase I signals, including roughly 30% average PVR reduction and about 38% peak PVR reduction, with good tolerability and limited systemic side effects.
• Roivant said its PH-ILD Phase II study is fully enrolled at 135 patients, the vast majority reached the target dose, and topline data is expected in the second half of 2026; the company also reiterated a strong cash position of $4.3 billion pre-Moderna settlement.

Roivant Sciences Trading Down 1.4%

Shares of NASDAQ ROIV traded down $0.46 during mid-day trading on Thursday, reaching $31.95. The company had a trading volume of 755,314 shares, compared to its average volume of 6,029,282. Roivant Sciences has a 1-year low of $10.59 and a 1-year high of $32.79. The stock has a market cap of $22.87 billion, a PE ratio of -27.31 and a beta of 1.14. The company has a 50-day moving average price of $28.43 and a two-hundred day moving average price of $24.95.

More Roivant Sciences News

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Roivant beat earnings expectations for the quarter, reporting an adjusted EPS of $0.28 versus consensus near a loss, helping drive investor optimism around the company’s improving profitability. Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
• Positive Sentiment: Management pointed to major near-term pipeline and business catalysts, including an anticipated $950 million Moderna-related payment in July and second-half 2026 readouts for mosliciguat and IMVT-1402. Roivant anticipates $950M Moderna payment in July as it outlines 2H 2026 mosliciguat and IMVT-1402 readouts
• Positive Sentiment: Investor sentiment was also supported by strength in Roivant affiliate Immunovant, whose trial results were described as clinically meaningful, reinforcing the value of Roivant’s broader biotech pipeline. 2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug
• Neutral Sentiment: The quarter was not uniformly strong, as revenue missed estimates and the company remains unprofitable on a net basis, leaving some questions about the durability of the rally. Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
• Neutral Sentiment: Options activity showed unusually heavy put buying, suggesting some traders were hedging or betting on volatility around the earnings announcement.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Jefferies Financial Group reissued a “buy” rating on shares of Roivant Sciences in a research report on Tuesday, March 3rd. Weiss Ratings reiterated a “sell (d)” rating on shares of Roivant Sciences in a research note on Friday, May 8th. Sanford C. Bernstein assumed coverage on shares of Roivant Sciences in a research note on Friday, March 20th. They issued an “outperform” rating and a $35.00 target price on the stock. Guggenheim lifted their target price on shares of Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a report on Monday, February 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $34.00 price target on shares of Roivant Sciences in a research report on Thursday. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $31.55.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the business’s stock in a transaction on Monday, April 20th. The shares were sold at an average price of $29.59, for a total transaction of $5,918,000.00. Following the sale, the chief executive officer directly owned 1,647,546 shares of the company’s stock, valued at $48,750,886.14. The trade was a 10.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Jennifer Humes sold 13,538 shares of the business’s stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $28.37, for a total transaction of $384,073.06. Following the transaction, the chief accounting officer directly owned 84,191 shares in the company, valued at $2,388,498.67. The trade was a 13.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 2,345,173 shares of company stock worth $65,251,917 in the last three months. Insiders own 10.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. grew its stake in shares of Roivant Sciences by 15.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock valued at $24,553,000 after buying an additional 324,764 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Roivant Sciences by 1.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after purchasing an additional 34,341 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of Roivant Sciences by 1.9% in the 2nd quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock valued at $1,010,000 after purchasing an additional 1,689 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in Roivant Sciences by 149.9% in the second quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock worth $129,000 after purchasing an additional 6,879 shares in the last quarter. Finally, M&T Bank Corp raised its holdings in Roivant Sciences by 10.2% during the second quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock valued at $144,000 after buying an additional 1,181 shares in the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.